Archives
-
ALDOB K87 Lactylation in Pulmonary Hypertension
2026-09-09
This study identifies ALDOB K87 lactylation as a mechanistic link between hypoxia-driven glycolytic remodeling, mitochondrial fission, and pulmonary artery smooth muscle cell pathology. Its lactate–ALDOB–DRP1 model provides a framework for interpreting metabolic post-translational modifications as regulators of pulmonary hypertension progression and for designing site-specific validation experiments.
-
AO/PI Staining Solution for Kidney Research
2026-09-09
AO/PI Staining Solution combines two fluorescent DNA dyes to deliver rapid live/dead cell discrimination in podocyte, PBMC, and kidney-tissue workflows. Its membrane-integrity readout complements mechanistic studies of phillygenin, inflammation, and apoptosis by adding a quantitative viability checkpoint before downstream analysis.
-
Hepatic sEH, Nrf2, and Osteoporosis
2026-09-08
The reference study identifies a liver–bone signaling axis in which hepatic soluble epoxide hydrolase alters circulating 14,15-EET and 14,15-DHET, suppressing Nrf2-ARE activity and promoting osteoclast differentiation. Its combination of clinical samples, ovariectomy-induced osteoporosis, liver-specific knockdown, pharmacological inhibition, and transcriptomics provides a mechanistic framework for studying redox imbalance in bone disease.
-
3-Deazaneplanocin (DZNep): Mechanism & Uses
2026-09-08
3-Deazaneplanocin (DZNep) is a S-adenosylhomocysteine hydrolase inhibitor and epigenetic modulator that suppresses EZH2-associated histone H3 lysine 27 trimethylation. Preclinical data support its use in apoptosis induction in AML cells, hepatocellular carcinoma research, and cancer stem cell targeting, while its context-dependent effects require orthogonal mechanistic controls.
-
Fluorouracil: Modeling Response Heterogeneity
2026-09-07
Fluorouracil and 5-Fluorouracil are powerful tools for studying thymidylate synthase blockade, replication stress, and variable tumor response. This article translates colorectal cancer evolution research into a heterogeneity-aware framework for mechanistic assays and preclinical study design.
-
In Vitro Drug Response Evaluation in Cancer
2026-09-07
Hannah Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. By separating growth inhibition from cell killing and considering their timing, the study provides a more precise framework for interpreting drug responses and designing mechanistic cancer assays.
-
Angiotensin II: Mechanism and Research Use
2026-09-05
Angiotensin II, also called Asp-Arg-Val-Tyr-Ile-His-Pro-Phe, is an endogenous octapeptide and potent vasopressor that activates angiotensin GPCRs. Its receptor signaling supports hypertension mechanism study, vascular remodeling, and controlled cardiovascular disease models, but experimental dose and model context determine interpretation.
-
Mitomycin C Workflows for Apoptosis Research
2026-09-04
Mitomycin C turns DNA adduct formation into a controllable platform for DNA replication inhibition, apoptosis mapping, and TRAIL sensitization. This practical guide covers dosing, combination design, cell-state controls, and troubleshooting across PC3 and colon cancer model workflows.
-
AZD2461 Assay Design for Reliable PARP Studies
2026-09-04
This scenario-based guide explains how AZD2461, SKU A4164, can support interpretable cell viability, proliferation, and cytotoxicity assays in breast cancer research. It connects PARP biology with practical dose design, formulation control, endpoint selection, and evidence-based reagent sourcing.
-
ATRA Reverses Cisplatin-Associated PARP Resistance
2026-09-03
A 2025 study in Molecular Cancer Therapeutics shows that all-trans retinoic acid can reduce cisplatin-induced resistance to PARP inhibition in epithelial ovarian cancer models. Sequential cisplatin treatment followed by niraparib maintenance with ATRA improved tumor control and survival in preclinical systems, while implicating ALDH1A1, NAMPT, PARP1, CHEK1, and intracellular NAD+ as components of the resistant state.
-
AZD1390: ATM Kinase Inhibitor Workflow
2026-09-03
AZD1390 enables concentration-controlled ATM inhibition for radiation, replication-stress, and glioblastoma models. Its strongest use-case is a mechanistic workflow that connects double-strand-break signaling with emerging REV1–DHX36 control of G-quadruplex DNA tolerance.
-
AZD1390 ATM Kinase Inhibitor Workflow
2026-09-02
AZD1390 enables precise interrogation of ATM-dependent DNA damage signaling and radiation response in glioma and lung cancer models. This workflow combines validated radiosensitization conditions with exploratory assays for G-quadruplex replication stress, helping distinguish checkpoint failure from direct repair defects.
-
Sulfisomidine: A Matrix-Aware Research Framework
2026-09-02
Sulfisomidine, also known as sulfamethin, is more than a sulfonamide antibacterial: it is a mechanistic probe for folate biology, hPON1 inhibition, and transformation-product research. This guide connects enzyme assay design with environmental fate analysis to improve interpretation and reproducibility.
-
Geneticin, G-418 Sulfate: Selection Guide
2026-09-01
Geneticin, G-418 Sulfate (SKU A2513) provides selective pressure for cells carrying a neomycin resistance gene and can support defined antiviral experiments involving Dengue virus serotype 2. Its working concentration must be optimized by cell type and assay; the dossier range is not a substitute for a cell-line-specific kill curve or cytotoxicity control.
-
Platelet Extravasation into Tumors: Molecular Control
2026-09-01
The reference study establishes that platelet entry into tumors is an actively regulated process rather than passive leakage from abnormal vessels. It identifies stromal CXCL12–CXCR4 signaling, platelet FAK and PECAM-1, and distinct granule-release pathways as separable controls of platelet trafficking, vascular integrity, and tumor growth.